A Single-Arm, Open-Label, Multi-Center, Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Linperlisib (Primary)
- Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Yingli Pharmaceutical
Most Recent Events
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results (n=43) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 11 Jun 2021 According to a Yingli Pharma media release, data from this study were presented at the American Society for Clinical Oncology 2021 Annual Meeting.